/EINPresswire.com/ -- SYDNEY, AUSTRALIA -- (Marketwired) -- 02/25/16 -- Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company") is pleased to announce the results of the Special Meeting of the Company's shareholders which was held at 10:00 am today (Australian Eastern Daylight Time) in North Sydney, Australia.

All three resolutions that were put before the meeting were passed unanimously on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of special meeting and information circular are contained in the following table.

----------------------------------------------------------------------------
Description of Resolution              For     Against   Abstain      Totals
----------------------------------------------------------------------------
1. Approval and ratification of First Tranche Placement
----------------------------------------------------------------------------
   Numbers of votes received    36,335,306     853,878    68,536  37,257,720
                                                                ------------
   Percentage of votes cast         97.52%       2.29%     0.18%     100.00%
----------------------------------------------------------------------------
2. Approve and Authorization of Second Tranche Placement
----------------------------------------------------------------------------
   Numbers of votes received    38,528,190     853,878    68,536  39,450,604
                                                                ------------
   Percentage of votes cast         97.66%       2.16%     0.17%     100.00%
----------------------------------------------------------------------------
3. Approval and Authorization of Issue of Common Shares and Placement
 Options to Dussman Pty Ltd
----------------------------------------------------------------------------
   Numbers of votes received     7,003,526     868,078    85,536   7,957,140
                                                                ------------
   Percentage of votes cast         88.02%      10.91%     1.07%     100.00%
----------------------------------------------------------------------------

About Simavita

Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM®

SIM® is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM® provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM® is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM®, please visit www.simavita.com.

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Contacts:
Company
Philippa Lewis
Chief Executive Officer
+61 2 8405 6381

Media and Investor Relations
Glen Zurcher
+61 420 249 299
glen.zurcher@irdepartment.com.au
www.simavita.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.